ABOUT THE EVENT
What you'll learn: Vaccine safety data, policymaking, and science communication
- Sex and gender dimensions in COVID-19 vaccines, and its considerations in policy decision-making, and science communication for the public
- Lessons from past knowledge of sex-based differences in vaccine science and policy decision-making, including use of sex-disaggregated data and gender analysis in regulatory evaluations
- Current opportunities to respond to the biological differences in women and men in COVID-19 vaccine research and consequent deployment
- The path to ‘do better’ in addressing the sex and gender dimensions in vaccine and pharmaceutical R&D, policy-making and science communication process
Watch the full webinar HERE.
What's it about?
Stronger considerations of sex and gender factors in the COVID-19 vaccine R&D and data reporting process, policy decision-making, and science communication to the public can contribute to better science and innovation, and prevent avoidable harm in a timely manner. For this to happen, solidarity in commitment, cohesive practice, and open dialogue on the challenges and proposed solutions are imperative, so that sex and gender considerations are not ‘deprioritised’ in the current moment.
Who is part of it?
This session will be chaired by Shirin Heidari from GENDRO.
Presenters:
- Tracey Goodman, WHO
- Lavanya Vijayasingham, UNU-IIGH
Moderator:
- Jean Munro, GAVI
Panellists:
- Apoorva Mandavilli, Journalist, The New York Times
- Professor Noni MacDonald, Dalhousie University, Canada
- Professor Saad Omer, Yale University, USA
Watch the full webinar HERE.